We, ARCE Therapeutics, Inc., specialize in developing first and best-in-class gene-modified cellular therapy including chimeric antigen receptor T (CAR-T) and CAR-NK cell therapy for finding cures for human hematological malignancies and solid tumors. The idea is to rewire our own immune system with a targeting “GPS” for fighting cancers; it involves genetic modifications of patient’s immune cells followed by ex vivo cell expansion and re-infusion back to the patient. Despite the remarkable outcomes and FDA approvals of CD19 and BCMA CAR-Ts in treating blood cancers, there are challenges to be addressed in reducing toxicity, tackling solid tumors, and lowering cost of such amazing living drugs. ARCE’s CAR cell therapy products are developed via three technologies, DashCARTM, MaxCARTM, and OneCARTM. Each technology is implemented to tackle key challenges and to meet the unmet medical needs. Our R&D has made significant progress in fast manufacturing of DashCAR-T cells and we are advancing the system and expected to start human clinical trials in Q2, 2024 in the U.S. and in Taiwan. Through our innovative immune cell therapy and commercialization development, ARCE provides state-of-the-art products of new generation CAR-T/NK cell therapy, to make it faster, better, safer, and more accessible to patients.